Skip to content
AlternativeMed

Why Different Substances Cannot Be Treated as Equivalent

Why psilocybin, LSD, mescaline, DMT, MDMA, ketamine, ibogaine, salvia and Amanita compounds differ in origin, action, risks and regulatory status, and cannot be treated as interchangeable.

Content last updated . This page has not been medically reviewed.

One heading, many different substances

"Psychedelics" is often used as a single word for very different things. Sources used by this library describe different origins, different main brain systems, different documented risks and different regulatory standing. A finding about one substance, preparation or condition does not automatically apply to another.

Side by side

SubstanceGroup in the sourcesOriginMain action describedNotable documented point
PsilocybinClassic psychedelic [1]Certain mushrooms [2]Mostly 5-HT2A, but at many serotonin receptors [3]Breakthrough Therapy designation for two formulations in depression research [4]
LSDClassic psychedelic [1]Semisynthetic [5]Serotonin 5-HT2A [1]Chemically related to serotonin [5]
MescalineClassic psychedelic [1]Cacti such as peyote [6]5-HT2A/2C plus other receptors [6]US federal rules exempt nondrug peyote use in bona fide Native American Church ceremonies from the Schedule I listing (21 CFR 1307.31, read 2026-10-22); laws change [7]
DMTClassic psychedelic [1]Leaves of Psychotria viridis, a plant in ayahuasca [8]5-HT1A/2A partial agonist [8]Ayahuasca also contains other compounds such as beta-carbolines [8]
MDMA"Other" group [1]Synthetic [9]Releases serotonin, dopamine, norepinephrine [9]Heat-related and interaction risks; Breakthrough designation for PTSD research [9][4]
KetamineDissociative [1]Laboratory-developed anesthetic [10]Blocks NMDA receptors [1]FDA approved as an anesthetic; not approved for a mental health disorder [10]
EsketamineKetamine derivative [10]Derived from ketamine [10]See the esketamine guideFDA approved for treatment-resistant depression in adults [10]
Ibogaine"Other" group [1]Shrub Tabernanthe iboga [11]Variety of receptors [1]Associated with long QT syndrome [1]
Salvinorin A (salvia)"Other" group [1]Salvia divinorum [12]Kappa opioid receptors [1]Mazatec use for centuries [12]
Muscimol and ibotenic acidOutside the classic group; acts on GABA [13]Amanita muscaria [14]Potent GABA agonists [13]Case reports of serious toxicity including a death [15]

The table is a map, not a ranking. It says nothing about which substance is "stronger" or "better", and this library gives no comparisons of amounts or potency between substances, species or preparations. NIDA notes that amount, potency, a person's biology and the setting all influence effects. [1]

Why "interchangeable" is the wrong idea

  • Different receptors. Serotonin 5-HT2A, NMDA, kappa opioid and GABA systems are all involved across this list. See Serotonin Receptors in Plain Language.
  • Different risk profiles. NIDA ties long-term ketamine use to bladder problems, MDMA to possible heart valve disease in limited research, and ibogaine to long QT syndrome. [1]
  • Different evidence. FDA says psychedelic drug programs are subject to the same regulations and evidentiary standards as other drug development programs, which means each product and use must meet them on its own. [16] Not every substance has been studied for every condition. See Psychedelic Clinical Trials and Research Limits.
  • Different forms. A mushroom, a cactus, a brew, a purified compound and a clinical product are not the same thing. See Traditional Preparations vs Isolated Compounds and Clinical Products.
  • Different cultural meanings. Plants such as peyote and iboga belong to specific peoples and traditions. See Indigenous Traditions, Ethics and Conservation.

Look-alike pairs that are not the same

Evidence labels

The table is classification and documented regulatory facts, not evidence of benefit. The label approved medicine applies, according to NIDA, to ketamine as an anesthetic and to esketamine for treatment-resistant depression. [4] Nothing else in the table carries that label.

Education only

This page compares categories. It gives no amounts, no sourcing, no combination advice and no advice to self-treat. If you take any medicine, see how interactions work.

Frequently asked questions

Can I assume what is true for psilocybin is true for LSD?

No. They are both classic psychedelics, but one comes from mushrooms and one is semisynthetic, and the research and regulatory histories differ. [2][5]

Are ketamine and esketamine the same?

No. NIDA says esketamine is a ketamine derivative approved for treatment-resistant depression in adults, while ketamine itself is not approved for any mental health disorder. [10]

Is MDMA a type of psychedelic?

It is grouped separately by NIDA, which says some researchers also consider it psychedelic. [1][9]

Do all of these substances act on serotonin?

No. Ketamine acts on NMDA receptors, salvia on kappa opioid receptors and muscimol on GABA receptors. [1][13]

Is there a ranking of safest to riskiest?

This library does not give one. Risks depend on the substance, form, person and setting. [1]

References

  1. National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
  2. National Institute on Drug Abuse, Psilocybin (Magic Mushrooms). Read 2026-10-22.
  3. Ling S et al. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. 2022;36(1):17-30. Read 2026-10-22 (abstract on PubMed).
  4. National Institute on Drug Abuse, Psychedelic and Dissociative Drugs as Medicines. Read 2026-10-22.
  5. Liester MB. A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects. Curr Drug Abuse Rev. 2014;7(3):146-56. Read 2026-10-22 (abstract on PubMed).
  6. Vamvakopoulou IA et al. Mescaline: The forgotten psychedelic. Neuropharmacology. 2023;222:109294. Read 2026-10-22 (abstract on PubMed).
  7. US Electronic Code of Federal Regulations, 21 CFR 1307.31 Native American Church. Read 2026-10-22.
  8. Dos Santos RG, Hallak JEC. Ayahuasca: pharmacology, safety, and therapeutic effects. CNS Spectr. 2024;30(1):e2. Read 2026-10-22 (abstract on PubMed).
  9. National Institute on Drug Abuse, MDMA (Ecstasy/Molly). Read 2026-10-22.
  10. National Institute on Drug Abuse, Ketamine. Read 2026-10-22.
  11. Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302. Read 2026-10-22 (abstract on PubMed).
  12. Grundmann O et al. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology. Planta Med. 2007;73(10):1039-46. Read 2026-10-22 (abstract on PubMed).
  13. Okhovat A et al. Psychoactive Isoxazoles, Muscimol, and Isoxazole Derivatives from the Amanita (Agaricomycetes) Species: Review of New Trends in Synthesis, Dosage, and Biological Properties. Int J Med Mushrooms. 2023;25(9):1-10. Read 2026-10-22 (abstract on PubMed).
  14. Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003;107(Pt 2):131-46. Read 2026-10-22 (abstract on PubMed).
  15. Meisel EM et al. Two Cases of Severe Amanita Muscaria Poisoning Including a Fatality. Wilderness Environ Med. 2022;33(4):412-416. Read 2026-10-22 (abstract on PubMed).
  16. US Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (July 2026). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.